Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 4/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837319 | 0.89 | ACHE (0.42) | ACHEL3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4837054 | 0.87 | KDM4E (0.41) | ACHEL3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4832702 | 0.87 | GAA (0.41) | ACHEL3MBTL3L3MBTL1KDM4ESSTR1 | |
| SCHEMBL4840385 | 0.83 | ACACB (0.41) | ACHEL3MBTL3L3MBTL1F10F2 | |
| SCHEMBL6215877 | 0.82 | ACHE (0.52) | ACHEL3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4838454 | 0.82 | ALDH1A1 (0.40) | ACHEL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4840253 | 0.80 | KDM4E (0.45) | ACHEL3MBTL3L3MBTL1CCR3KDM4E | |
| Hydrochloric Acid SCHEMBL4841921 | 0.80 | KDM4E (0.44) | ACHEL3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4841021 | 0.79 | ACKR3 (0.41) | ACHEL3MBTL3L3MBTL1F10F2 | |
| SCHEMBL4832878 | 0.76 | ACHE (0.39) | ACHEL3MBTL3L3MBTL1F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-6946467-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | ACHE 3190/4885L3MBTL3 591/4885L3MBTL1 116/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ACHE 2174/4885L3MBTL3 1408/4885L3MBTL1 332/4885 |
| US-20040176363-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ACHE 2174/4885L3MBTL3 1408/4885L3MBTL1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.